Skip to main content
Top
Published in: Journal of Translational Medicine 1/2020

01-12-2020 | Myocarditis | Research

Changes in heart morphometric parameters over the course of a monocrotaline-induced pulmonary arterial hypertension rat model

Authors: Mateusz K. Hołda, Elżbieta Szczepanek, Joanna Bielawska, Natalia Palka, Dorota Wojtysiak, Paulina Frączek, Michał Nowakowski, Natalia Sowińska, Zbigniew Arent, Piotr Podolec, Grzegorz Kopeć

Published in: Journal of Translational Medicine | Issue 1/2020

Login to get access

Abstract

Background

Aim of this study was to assess changes in cardiac morphometric parameters at different stages of pulmonary arterial hypertension (PAH) using a monocrotaline-induced rat model.

Methods

Four groups were distinguished: I–control, non-PAH (n = 18); II–early PAH (n = 12); III–end-stage PAH (n = 23); and IV–end-stage PAH with myocarditis (n = 7).

Results

Performed over the course of PAH in vivo echocardiography showed significant thickening of the right ventricle free wall (end-diastolic dimension), tricuspid annular plane systolic excursion reduction and decrease in pulmonary artery acceleration time normalized to cycle length. No differences in end-diastolic left ventricle free wall thickness measured in echocardiography was observed between groups. Significant increase of right ventricle and decrease of left ventricle systolic pressure was observed over the development of PAH. Thickening and weight increase (241.2% increase) of the right ventricle free wall and significant dilatation of the right ventricle was observed over the course of PAH (p < 0.001). Reduction in the left ventricle free wall thickness was also observed in end-stage PAH (p < 0.001). Significant trend in the left ventricle free wall weight decrease was observed over the course of PAH (p < 0.001, 24.3% reduction). Calculated right/left ventricle free wall weight ratio gradually increased over PAH stages (p < 0.001). The reduction of left ventricle diameter was observed in rats with end-stage PAH both with and without myocarditis (p < 0.001).

Conclusions

PAH leads to multidimensional changes in morphometric cardiac parameters. Right ventricle morphological and functional failure develop gradually from early stage of PAH, while left ventricle changes develop at the end stages of PAH.
Literature
1.
go back to reference Hoeper MM, Ghofrani H-A, Grunig E, Klose H, Olschewski H, Rosenkranz S. Pulmonary hypertension. Dtsch Arztebl Int. 2017;114(5):73–84.PubMed Hoeper MM, Ghofrani H-A, Grunig E, Klose H, Olschewski H, Rosenkranz S. Pulmonary hypertension. Dtsch Arztebl Int. 2017;114(5):73–84.PubMed
2.
go back to reference Rain S, Handoko ML, Vonk Noordegraaf A, Bogaard HJ, van der Velden J, de Man FS. Pressure-overload-induced right heart failure. Pflügers Arch Eur J Physiol. 2014;466(6):1055–63. Rain S, Handoko ML, Vonk Noordegraaf A, Bogaard HJ, van der Velden J, de Man FS. Pressure-overload-induced right heart failure. Pflügers Arch Eur J Physiol. 2014;466(6):1055–63.
3.
go back to reference Rosenkranz S, Gibbs JSR, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry J-L. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37(12):942–54.CrossRef Rosenkranz S, Gibbs JSR, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry J-L. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37(12):942–54.CrossRef
4.
go back to reference McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976–97.CrossRef McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976–97.CrossRef
5.
go back to reference Kopeć G, Moertl D, Miszalski-Jamka T, Waligóra M, Tyrka A, Sarnecka A, et al. Left ventricular mass is preserved in patients with idiopathic pulmonary arterial hypertension and eisenmenger’s syndrome. Heart Lung Circ. 2014;23(5):454–61.CrossRef Kopeć G, Moertl D, Miszalski-Jamka T, Waligóra M, Tyrka A, Sarnecka A, et al. Left ventricular mass is preserved in patients with idiopathic pulmonary arterial hypertension and eisenmenger’s syndrome. Heart Lung Circ. 2014;23(5):454–61.CrossRef
6.
go back to reference Hardziyenka M, Campian ME, Reesink HJ, Surie S, Bouma BJ, Groenink M, et al. Right ventricular failure following chronic pressure overload is associated with reduction in left ventricular mass: evidence for atrophic remodeling. J Am Coll Cardiol. 2011;57(8):921–8.CrossRef Hardziyenka M, Campian ME, Reesink HJ, Surie S, Bouma BJ, Groenink M, et al. Right ventricular failure following chronic pressure overload is associated with reduction in left ventricular mass: evidence for atrophic remodeling. J Am Coll Cardiol. 2011;57(8):921–8.CrossRef
7.
go back to reference Dell’Italia LJ. The forgotten left ventricle in right ventricular pressure overload. J Am Coll Cardiol. 2011;57(8):929–30.CrossRef Dell’Italia LJ. The forgotten left ventricle in right ventricular pressure overload. J Am Coll Cardiol. 2011;57(8):929–30.CrossRef
8.
go back to reference Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(16):1527–38.CrossRef Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(16):1527–38.CrossRef
9.
go back to reference Bossone E, D’Andrea A, D’Alto M, Citro R, Argiento P, Ferrara F, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr. 2013;26(1):1–14.CrossRef Bossone E, D’Andrea A, D’Alto M, Citro R, Argiento P, Ferrara F, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr. 2013;26(1):1–14.CrossRef
10.
go back to reference Fischer L, Benjamin N, Blank N, Egenlauf B, Fischer C, Harutyunova S, et al. Right heart size and function significantly correlate in patients with pulmonary arterial hypertension—a cross-sectional study. Respir Res. 2018;19(1):216.CrossRef Fischer L, Benjamin N, Blank N, Egenlauf B, Fischer C, Harutyunova S, et al. Right heart size and function significantly correlate in patients with pulmonary arterial hypertension—a cross-sectional study. Respir Res. 2018;19(1):216.CrossRef
11.
go back to reference Maarman G, Lecour S, Butrous G, Thienemann F, Sliwa K. A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? Pulm Circ. 2013;3(4):739–56.CrossRef Maarman G, Lecour S, Butrous G, Thienemann F, Sliwa K. A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? Pulm Circ. 2013;3(4):739–56.CrossRef
12.
go back to reference Hardziyenka M, Campian ME, de Bruin-Bon HA, Michel MC, Tan HL. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiogr. 2006;19(10):1272–9.CrossRef Hardziyenka M, Campian ME, de Bruin-Bon HA, Michel MC, Tan HL. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiogr. 2006;19(10):1272–9.CrossRef
13.
go back to reference Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Hear Circ Physiol. 2006;291(5):H2424–30.CrossRef Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Hear Circ Physiol. 2006;291(5):H2424–30.CrossRef
14.
go back to reference Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Hear J Cardiovasc Imaging. 2015;16(3):233–70.CrossRef Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Hear J Cardiovasc Imaging. 2015;16(3):233–70.CrossRef
15.
go back to reference Akhavein F, St-Michel EJ, Seifert E, Rohlicek CV. Decreased left ventricular function, myocarditis, and coronary arteriolar medial thickening following monocrotaline administration in adult rats. J Appl Physiol. 2007;103(1):287–95.CrossRef Akhavein F, St-Michel EJ, Seifert E, Rohlicek CV. Decreased left ventricular function, myocarditis, and coronary arteriolar medial thickening following monocrotaline administration in adult rats. J Appl Physiol. 2007;103(1):287–95.CrossRef
16.
go back to reference Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell sections. Cold Spring Harb Protoc. 2008;6:prot4986. Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell sections. Cold Spring Harb Protoc. 2008;6:prot4986.
17.
go back to reference Mak SM, Strickland N, Gopalan D. Complications of pulmonary hypertension: a pictorial review. Br J Radiol. 2017;90(1070):20160745.CrossRef Mak SM, Strickland N, Gopalan D. Complications of pulmonary hypertension: a pictorial review. Br J Radiol. 2017;90(1070):20160745.CrossRef
18.
go back to reference van der Bruggen CEE, Tedford RJ, Handoko ML, van der Velden J, de Man FS. RV pressure overload: from hypertrophy to failure. Cardiovasc Res. 2017;113(12):1423–32.CrossRef van der Bruggen CEE, Tedford RJ, Handoko ML, van der Velden J, de Man FS. RV pressure overload: from hypertrophy to failure. Cardiovasc Res. 2017;113(12):1423–32.CrossRef
19.
go back to reference Aguero J, Ishikawa K, Hadri L, Santos-Gallego C, Fish K, Hammoudi N, et al. Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model. Am J Physiol Heart Circ Physiol. 2014;307(8):H1204–15.CrossRef Aguero J, Ishikawa K, Hadri L, Santos-Gallego C, Fish K, Hammoudi N, et al. Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model. Am J Physiol Heart Circ Physiol. 2014;307(8):H1204–15.CrossRef
20.
go back to reference D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115(5):343–9.CrossRef D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115(5):343–9.CrossRef
21.
go back to reference Prins KW, Thenappan T. World Health Organization Group I pulmonary hypertension: epidemiology and pathophysiology. Cardiol Clin. 2016;34:363–74.CrossRef Prins KW, Thenappan T. World Health Organization Group I pulmonary hypertension: epidemiology and pathophysiology. Cardiol Clin. 2016;34:363–74.CrossRef
22.
go back to reference Han JC, Guild SJ, Pham T, Nisbet L, Tran K, Taberner AJ, et al. Left-ventricular energetics in pulmonary arterial hypertension-induced right-ventricular hypertrophic failure. Front Physiol. 2017;8:1115.CrossRef Han JC, Guild SJ, Pham T, Nisbet L, Tran K, Taberner AJ, et al. Left-ventricular energetics in pulmonary arterial hypertension-induced right-ventricular hypertrophic failure. Front Physiol. 2017;8:1115.CrossRef
23.
go back to reference Goerne H, Batra K, Rajiah P. Imaging of pulmonary hypertension: an update. Cardiovasc Diagn Ther. 2018;8:279–96.CrossRef Goerne H, Batra K, Rajiah P. Imaging of pulmonary hypertension: an update. Cardiovasc Diagn Ther. 2018;8:279–96.CrossRef
24.
go back to reference Bueno-Beti C, Sassi Y, Hajjar RJ, Hadri L. Pulmonary artery hypertension model in rats by monocrotaline administration. Methods Mol Biol. 2018;1816:233–41.CrossRef Bueno-Beti C, Sassi Y, Hajjar RJ, Hadri L. Pulmonary artery hypertension model in rats by monocrotaline administration. Methods Mol Biol. 2018;1816:233–41.CrossRef
25.
go back to reference Naeije R, Manes A. The right ventricle in pulmonary arterial hypertension. Eur Respir Rev. 2014;23:476–87.CrossRef Naeije R, Manes A. The right ventricle in pulmonary arterial hypertension. Eur Respir Rev. 2014;23:476–87.CrossRef
26.
go back to reference Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J. 2012;40(6):1555–65.CrossRef Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J. 2012;40(6):1555–65.CrossRef
27.
go back to reference Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ. Mechanisms of right heart failure—A work in progress and a plea for failure prevention. Pulm Circ. 2013;3(1):137–43.CrossRef Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ. Mechanisms of right heart failure—A work in progress and a plea for failure prevention. Pulm Circ. 2013;3(1):137–43.CrossRef
28.
go back to reference Meyer M. Left ventricular atrophy in pulmonary arterial hypertension: a sinister dexter conundrum. J Am Coll Cardiol. 2014;64(1):38–40.CrossRef Meyer M. Left ventricular atrophy in pulmonary arterial hypertension: a sinister dexter conundrum. J Am Coll Cardiol. 2014;64(1):38–40.CrossRef
29.
go back to reference Baskin KK, Taegtmeyer H. Taking pressure off the heart: the ins and outs of atrophic remodelling. Cardiovasc Res. 2011;90(2):243–50.CrossRef Baskin KK, Taegtmeyer H. Taking pressure off the heart: the ins and outs of atrophic remodelling. Cardiovasc Res. 2011;90(2):243–50.CrossRef
30.
go back to reference Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012;302(4):L363–9.CrossRef Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012;302(4):L363–9.CrossRef
31.
go back to reference Campian ME, Hardziyenka M, Michel MC, Tan HL. How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol. 2006;373(6):391–400.CrossRef Campian ME, Hardziyenka M, Michel MC, Tan HL. How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol. 2006;373(6):391–400.CrossRef
32.
go back to reference Nogueira-Ferreira R, Vitorino R, Ferreira R, Henriques-Coelho T. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: a network approach. Pulm Pharmacol Ther. 2015;35:8–16.CrossRef Nogueira-Ferreira R, Vitorino R, Ferreira R, Henriques-Coelho T. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: a network approach. Pulm Pharmacol Ther. 2015;35:8–16.CrossRef
33.
go back to reference Hirokawa E, Kotani T, Yamate J, Kuwamura M, Sakuma S. Myocardiopathy and expression of atrial natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension. J Vet Med Sci. 1994;56(4):651–5.CrossRef Hirokawa E, Kotani T, Yamate J, Kuwamura M, Sakuma S. Myocardiopathy and expression of atrial natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension. J Vet Med Sci. 1994;56(4):651–5.CrossRef
Metadata
Title
Changes in heart morphometric parameters over the course of a monocrotaline-induced pulmonary arterial hypertension rat model
Authors
Mateusz K. Hołda
Elżbieta Szczepanek
Joanna Bielawska
Natalia Palka
Dorota Wojtysiak
Paulina Frączek
Michał Nowakowski
Natalia Sowińska
Zbigniew Arent
Piotr Podolec
Grzegorz Kopeć
Publication date
01-12-2020

Other articles of this Issue 1/2020

Journal of Translational Medicine 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.